DR. ROBERT IRWIN HENKIN, MD PHD
Neurology at Macarthur Blvd, Washington, DC

4066405, Jan 3, 1978

Oct 4, 1976

5/729157

Robert I. Henkin - Bethesda MD

The United States of America as represented by the Department of Health,
Education and Welfare - Washington DC

G01N 3316, G01N 2100, G01N 2152, G01N 3108

23230B

A method for the total protein fractionation of saliva and for isolating a novel zinc protein found to be a component thereof is disclosed. Saliva was fractionated using three protein parameters and zinc concentration by a molecular sieving process. The zinc protein was isolated and purified from the saliva of subjects with normal taste acuity by gel filtration and ion exchange chromatography maximizing these parameters. The zinc protein has a molecular weight of 37,000 and does not appear to have subunits. It is composed of 8% histidine residues and has two moles of zinc per mole of protein. A decreased concentration of the protein in saliva has been associated with abnormal taste acuity.

7670849, Mar 2, 2010

May 1, 2006

11/415942

Robert I. Henkin - Bethesda MD, US

G01N 33/53, G01N 33/566, C12Q 1/54, A61K 38/28

436501, 435 71, 435 14, 435 30, 530303

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

3995031, Nov 30, 1976

Jul 23, 1974

5/490995

Robert I. Henkin - Bethesda MD
Eugene L. Giroux - Strasbourg, FR

The United States of America as represented by the Department of Health,
Education and Welfare - Washington DC

A61K 3700, A61K 3578

424177

A process for the purification of the active principle of the fruit of the plant Synsepalum dulcificum is disclosed. The process includes contacting the fruit with a suspension of polyvinyl pyrrolidone, followed by adsorption of the active principle by means of chromatography procedures. By following the process in accordance with the present invention, proteases and tannins are substantially completely eliminated from the final product. The active principle of this fruit, when prepared in accordance with the present invention, has been found to be particularly useful in controlling obesity in human beings.

4146501, Mar 27, 1979

Dec 27, 1976

5/753984

Robert I. Henkin - Bethesda MD

C09K 300, G01N 100, G01N 3114, G01N 3316

252408

A process for isolating and purifying taste bud receptor material for screening and evaluating tastants is described. The process includes surgically excising a plurality of circumvallate papillae, coring said papillae to remove the central mucous gland from each, followed by exposing the taste bud bearing epithelial portion thereof. The buds are preferably exposed by swelling in a hypotonic medium followed by subjecting said buds to about 900 psi in a nitrogen bomb. The swelled buds are then subjected to a gentle, selective homogenization to extrude taste bud receptor material therefrom without substantial destruction of surrounding epithelial tissue. The extruded material is then isolated by filtering and purified by subjecting the filtrate to differential centrifugation to isolate a receptor containing membrane enriched fraction. The fraction is then further purified by sucrose gradient centrifugation to isolate a receptor containing membrane enriched subfraction substantially without contaminating materials capable of binding tastants. The subfraction is then utilized as a medium for evaluating tastants wherein radioactive labeled tastant compounds are incubated with said subfraction until equilibrium is reached, and the quantity of labeled tastant is bound to the receptor material may then be measured.

8506934, Aug 13, 2013

Dec 29, 2009

12/649320

Robert I. Henkin - Bethesda MD, US

A61K 49/00, G01N 33/53, G01N 33/566, A61P 11/02

424 101, 436501, 435 71

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease. The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

2014007, Mar 13, 2014

Jul 1, 2013

13/932613

Robert I. Henkin - Bethesda MD, US

G01N 33/566, A61K 31/522

51426334, 435 792

The invention is directed to a method of detecting a biological substance in the nasal secretion and diagnosing a disease following the detection of the biological substance wherein the biological substance is not related to a respiratory disease. The invention also provides treatment of the diseases following the detection of the biological substance and/or diagnosis of the disease. In some embodiments, the diseases are cancer, hepatitis, smell loss, taste loss, diabetes, and leprosy. The invention also provides a kit for diagnosing a disease.The present invention includes methods of analyzing samples from the nose for the detection of biological substances. In particular, nasal secretion or nasal mucus is collected and analyzed for biological substances. The results of this analysis are then suitable for use in diagnosis, prognosis, and determination of suitability of therapeutic interventions.

8293489, Oct 23, 2012

Jan 31, 2008

12/523040

Robert I. Henkin - Bethesda MD, US

G01N 33/53, G01N 31/00

435 721, 435 71, 436501, 436518, 424 91, 424520, 422 50, 530300, 530350

Methods and compositions are provided for detection of biological substances in nasal specimen.

8580801, Nov 12, 2013

Jul 23, 2009

12/508530

Robert I. Henkin - Bethesda MD, US

A01N 43/90, A01N 43/42, A61K 31/522, A61K 31/47

51426334, 514312

Methods and compositions are disclosed for the treatment of diseases or conditions produced by or associated with low cyclic nucleotide levels. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal and pulmonary administration.